Explore By Subject Area   
Return Home
Menu

Lead Editorial

Aitia’s CEO Wants You to Use AI to Do More than Designing Drugs Against Known Validated Targets

Aitia’s CEO Wants You to Use AI to Do More than Designing Drugs Against Known Validated Targets

AI in the pharma R&D world isn’t just about designing better drugs against known drug targets, according to Aitia CEO Colin Hill. Mr Hill discusses how powerful AI can be in understanding novel human causal biology, creating novel drugs, and enhancing patient selection in clinical trials.

Read More

Featured Editorial

How Regeneron Is Applying Innovation to Modernize Clinical Trials

Read More

The Role of Generative AI in Making Better Immuno-Oncology Therapeutics

Read More

How J&J Innovative Medicine Applies Innovative Trial Designs for Patient Flexibility and Efficient Drug Development

Read More

Amgen Trial Operations Experts on What It Takes to Get an Innovative Trial Design Running

Read More

More Related Content

Editorial

How MIT Developed Invisible Remote Monitoring to Enhance Research

How MIT Developed Invisible Remote Monitoring to Enhance Research
Micky Tripathi and Amy Cramer on the Current State of Data Interoperability

Micky Tripathi and Amy Cramer on the Current State of Data Interoperability
Shaking Up How We Think About Data to Accelerate Clinical Research

Shaking Up How We Think About Data to Accelerate Clinical Research
Genentech’s Thoughtful Approach to Innovation that Actually Solves Problems in Clinical Trials

Genentech’s Thoughtful Approach to Innovation that Actually Solves Problems in Clinical Trials
How AbbVie Is Introducing Digital with Real Impact into Clinical Trials to Optimize Research

How AbbVie Is Introducing Digital with Real Impact into Clinical Trials to Optimize Research
How Did the DPHARM Idol Disrupt Winners Disrupt Clinical Research?

How Did the DPHARM Idol Disrupt Winners Disrupt Clinical Research?
Sponsors are Making Headway with Sites, but Blind Spots and Burdens Remain

Sponsors are Making Headway with Sites, but Blind Spots and Burdens Remain

Sponsored
The Operations Behind the First ALS Platform Trial, at Massachusetts General Hospital

The Operations Behind the First ALS Platform Trial, at Massachusetts General Hospital
Eisai’s SVP of Biostatistics on the Bayesian Trial for Early Alzheimer’s Disease

Eisai’s SVP of Biostatistics on the Bayesian Trial for Early Alzheimer’s Disease
Archive Highlight: How Memorial Sloan Kettering Developed and Scaled Remote Monitoring

Archive Highlight: How Memorial Sloan Kettering Developed and Scaled Remote Monitoring
Genentech’s Head of Digital Health on New Devices in Remote Monitoring

Genentech’s Head of Digital Health on New Devices in Remote Monitoring
How AstraZeneca Created a Chronic Disease Management System for Patients and Clinicians

How AstraZeneca Created a Chronic Disease Management System for Patients and Clinicians
Archive Highlight: Turning Data Science from Abstract to Reality, with Janssen’s Chief Data Science Officer

Archive Highlight: Turning Data Science from Abstract to Reality, with Janssen’s Chief Data Science Officer
Transforming Clinical Research with a Consumer Mindset

Transforming Clinical Research with a Consumer Mindset
BMS on Preparing Clinical Research for the Patient of the Future

BMS on Preparing Clinical Research for the Patient of the Future
Janssen Clinical Innovation Exec on Reimagining Clinical Trials from Start to Finish

Janssen Clinical Innovation Exec on Reimagining Clinical Trials from Start to Finish
What Data Informatics Could Do For Your Clinical Research Study, with an Informatics Expert

What Data Informatics Could Do For Your Clinical Research Study, with an Informatics Expert

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.